Myocardial Perfusion and Fibrosis in Cancer Survivors (NCT03191461) | Clinical Trial Compass
CompletedNot Applicable
Myocardial Perfusion and Fibrosis in Cancer Survivors
United States7 participantsStarted 2017-11-13
Plain-language summary
This is a cross-sectional pilot study. The investigators seek to obtain early information pertaining to the relationship between measurements of myocardial perfusion reserve and myocardial fibrosis after receipt of Anthracycline-based chemotherapy (≥2 years prior).
Who can participate
Age range21 Years – 85 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Cancer patients must have Stage I-III breast cancer or lymphoma and have received an anthracycline agent during treatment at least 2 years prior to enrollment in this study.
✓. Age-matched to cancer survivor with no history of cancer or anthracycline treatment.
✓. Age 21-85 years of age at the time of enrollment.
✓. ECOG or Karnofsky performance status of 0-1.
✓. Life expectancy of greater than 3 months.
✓. Enrolled control participants must have normal creatinine clearance of \>60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.
✓. Ability to understand and the willingness to sign an IRB-approved informed consent document (either directly or via a legally authorized representative).
Exclusion criteria
✕. History of allergic reactions attributed to compounds of similar chemical or biologic composition to gadolinium contrast agents or adenosine or history of kidney disease.
✕. Those with contraindications for MRI such as ferromagnetic cerebral aneurysm clips or other intracranial metal, pacemakers, defibrillators, functioning neurostimulator devices or other implanted electronic devices.
✕. Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
✕. Pregnant women are excluded from this study because the use of gadolinium in cardiac MRI imaging may not be safe in pregnant women. Because some methods of birth control are not 100% reliable, a pregnancy test is required if the participant is a) a sexually active woman of childbearing potential or b) a sexually active peri or post-menopausal women whose last normal menstrual period was less than 12 months ago.
✕. Coronary revascularization in the past 6 months or known severe multi-vessel CAD previously determined to be not amendable to mechanical intervention.
✕. Ongoing, unrelieved symptoms thought to represent cardiac ischemia and requiring immediate cardiac catheterization